Search

Displaying results 4781 - 4790 of 10000 in total
  1. Drug

    Cefadroxil

    go.drugbank.com/drugs/DB01140
    ApprovedInvestigationalVet approvedWithdrawn

    Long-acting, broad-spectrum, water-soluble, cephalexin derivative.

  2. Drug

    Repinotan

    go.drugbank.com/drugs/DB06506
    Investigational

    Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.

  3. Drug

    Pipamperone

    go.drugbank.com/drugs/DB09286
    Investigational

    It was developed by Janssen Pharmaceutica in 1961 and started its first round of clinical trials in 1963 [L1514, L1518]. … Pipamperone is a typical antipsychotic of the _butyrophenone_ family used in the treatment of schizophrenia.

  4. Drug

    Androstenedione

    go.drugbank.com/drugs/DB01536
    IllicitInvestigational

    A delta-4 C19 steroid that is produced not only in the testis, but also in the ovary and the adrenal cortex. … Depending on the tissue type, androstenedione can serve as a precursor to testosterone as well as estrone and estradiol.

  5. Drug

    Pracinostat

    go.drugbank.com/drugs/DB05223
    Investigational

    Pracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing. … Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors.

  6. Drug

    SNS-032

    go.drugbank.com/drugs/DB05969
    Investigational

  7. Drug

    Taribavirin

    go.drugbank.com/drugs/DB06408
    Investigational

  8. Drug

    7-Nitroindazole

    go.drugbank.com/drugs/DB02207
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    AV-412

    go.drugbank.com/drugs/DB06021
    Investigational

  10. Drug

    Bifeprunox

    go.drugbank.com/drugs/DB04888
    Investigational

    Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, [aripiprazole] and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.